Aurinia Pharmaceuticals Inc (AUPH)

[northern vortex]

I reject the premise that share dilution will be inevitable in order to complete the LN Phase 3 study.

Dr. Glickman can partner or sell off the Japanese rights to Voclosporin for LN and/or DES - with an upfront payment as part of the deal; or DES treatment rights for canines to Merck.

As Pencow pointed out (post 3771), there appears to be more than just potential value in the DES asset based on Merck’s participation in the collaborative research project.

Glickman just has to make the deal before the buyer knows AUPH needs the money in order to get the best price.